Antimicrobial Agents and Chemotherapy · 2005 · 46 citations · 24 references
PharmacyGynecologyToxicologyReproductive MedicineReproductive ToxicologyToxicodynamicsCervical InflammationCytotoxicity AssessmentCytotoxicity EvaluationCervical Epithelial InjuryCervicovaginal InflammationComparative Clinical TrialsCytotoxicity AssaysMucosal CytotoxicityVaginal GelsVaginal MicrobicidesVaginal Safety
C31G is currently the focus of clinical trials designed to evaluate this agent as a microbicidal and spermicidal agent. In the following studies, the in vivo safety of C31G was assessed with a Swiss Webster mouse model of cervicovaginal toxicity and correlated with results from in vitro cytotoxicity experiments and published clinical observations. A single exposure of unformulated 1% C31G resulted in mild-to-moderate epithelial disruption and inflammation at 2 and 4 h postapplication. The columnar epithelium of the cervix was the primary site of damage, while no perturbation of the vaginal mucosa was observed. In contrast, application of unformulated 1.7% C31G resulted in greater levels of inflammation in the cervical epithelium at 2 h postapplication and severe epithelial disruption that persisted to 8 h postapplication. Application of a nonionic aqueous gel formulation containing 1% C31G resulted in no apparent cervicovaginal toxicity at any time point evaluated. However, formulation of 1.7% C31G did not substantially reduce the toxicity associated with unformulated C31G at that concentration. These observations correlate with findings gathered during a recent clinical trial, in which once-daily applications resulted in no adverse events in women receiving the formulation containing 1% C31G, compared to moderate-to-severe adverse events in 30% of women receiving the 1.7% C31G formulation. The Swiss Webster mouse model was able to effectively discriminate between concentrations and formulations of C31G that produced distinct clinical effects in human trials. The Swiss Webster animal model may be a highly valuable tool for preclinical evaluation of candidate vaginal microbicides.
24
Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women
Marie Laga, A.T. Manoka, M. Kivuvu et al. · AIDS · 1993 · 1.1K citations
Medicine, Infectious Diseases, Infectious Disease Epidemiology +12
Raina N. Fichorova, James G. Rheinwald, Deborah J. Anderson · Biology of Reproduction · 1997 · 310 citations · Full text